Congestive heart failure and mitral regurgitation

Congestive Heart Failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Systolic Dysfunction Diastolic Dysfunction HFpEF HFrEF
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Other Imaging Studies
Other Diagnostic Studies
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Angiotensin Receptor-Neprilysin Inhibitor Antiarrhythmic Drugs Nutritional Supplements Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations Initial and Serial Evaluation of the HF Patient Hospitalized Patient Patients With a Prior MI Sudden Cardiac Death Prevention Surgical/Percutaneous/Transcather Interventional Treatments of HF Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D) Coordinating Care for Patients With Chronic HF Quality Metrics/Performance Measures
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF NSTEMI with Heart Failure and Cardiogenic Shock
Congestive heart failure and mitral regurgitation On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure and mitral regurgitation
CDC on Congestive heart failure and mitral regurgitation
Congestive heart failure and mitral regurgitation in the news
Blogs on Congestive heart failure and mitral regurgitation
Directions to Hospitals Treating Congestive heart failure and mitral regurgitation
Risk calculators and risk factors for Congestive heart failure and mitral regurgitation

Editor(s)-In-Chief: James Chang, M.D., Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School [1] and C. Michael Gibson, M.S., M.D. [2], Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School

Indications for MVr/R

1. Mitral regurgitation of 3+ or 4+

and any of the conditions below:

2. History of prior heart failure or congestive heart failure

or

3. Tricuspid regurgitation gradient ≥ 30 mmHg

or

4. History of prior atrial fibrillation

or

5. The left ventricular ejection fraction (LVEF) is ≤ 60%

or

6. The left ventricular end-systolic dimension is ≥ 40mm

Background

• Mitral regurgitation is highly associated with systolic heart failure as a cause, sequela, or complication. It confers independently and significantly increased mortality, regardless of its etiology or of the symptom status of the patient. Medical therapy has no significant impact on mortality associated with moderate to severe mitral regurgitation.

• Corrective intervention consists of mitral valve replacement (MVR) and mitral valve repair (MVr). Adhering to AHA guidelines for the timing of corrective intervention in patients with 3+/4+ mitral regurgitation is highly effective at improving or, in the subset of asymptomatic patients with normal left ventricular function, normalizing longevity.

• Mitral valve repair, when technically practicable, is associated with a superior hemodynamic and physiological result, with lower risk of hemorrhagic, thromboembolic, and infectious complications when compared with mitral valve replacement.

References

Template:WikiDoc Sources